Sarepta Therapeutics (SRPT) Common Equity (2010 - 2026)

Sarepta Therapeutics' Common Equity history runs 17 years deep, the most recent figure standing at $1.5 billion for Q1 2026.

• In Q1 2026, Common Equity rose 31.71% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $1.5 billion (up 31.71% YoY), while the FY2025 annual figure was $1.1 billion, down 25.34% from the prior year.
• Common Equity was $1.5 billion for Q1 2026 at Sarepta Therapeutics, up from $1.1 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.5 billion in Q4 2024 to a low of $385.0 million in Q4 2022.
• Historically, Common Equity has averaged $984.1 million across 5 years, with a median of $961.2 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Common Equity sank 58.52% in 2022, then surged 123.23% in 2023.
• A 5-year view of Common Equity shows it stood at $385.0 million in 2022, then surged by 123.23% to $859.3 million in 2023, then soared by 77.78% to $1.5 billion in 2024, then retreated by 25.34% to $1.1 billion in 2025, then jumped by 31.95% to $1.5 billion in 2026.
• The last three Common Equity figures came in at $1.5 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.